Skip to main content

Table 4 Differential changes of variables following placebo and calcitriol treatments in subjects with FF and Ff genotypes of the VDR FOKI polymorphism

From: The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism

Variable

FOKI FF genotype(n = 68)

FOKI Ff genotype (n = 58)

p-value

placebo

Calcitriol

placebo

Calcitriol

Group

Genotype

Interaction

weight, kg

−0.16 ± 2.4

0.24 ± 1.8-

− 1.0 ± 2.3

0.5 ± 3.8-

0.67

0.24

0.57

BMI, kg/m2

0.00 ± 0.75-

−0.21 ± 1.0

− 0.36 ± 0.8

0.2 ± 1.3-

0.89

0.35

0.34

WC, cm

−0.8 ± 1.8

0.12 ± 2.8

−0.8 ± 1.9

−0.3 ± 2.0

0.10

0.58

0.55

HC, cm

0.16 ± 3.4

0.8 ± 3.6-

−0.6 ± 1.4

− 0.6 ± 3.0

0.37

0.58

0.39

FBS, mg/dl

−2.0 ± 13.5

2.0 ± 19.3

1.3 ± 9.1

−4.6 ± 42.8

0.82

0.71

0.27

Insulin

−0.05 ± 6.8

0.12 ± 6.4

0.2 ± 6.7

0.1 ± 4.6

0.97

0.90

0.91

Homa-IR

−0.2 ± 0.7

0.1 ± 1.3

0.08 ± 0.9

− 0.2 ± 1.0

0.74

0.90

0.09

TC, mg/dl

−4.5 ± 60.1

−7.8 ± 33.7

1.6 ± 46.1

−8.8 ± 47.4

0.43

0.86

0.68

TG.mg/dl

−8.1 ± 95.1

−29.2 ± 99.8

5.3 ± 83.2

1.0 ± 82.0

0.46

0.20

0.62

HDL -C, mg/dl

−2.2 ± 10.9

−3.1 ± 9.7

1.4 ± 8.8

−1.2 ± 11.0

0.34

0.14

0.66

LDL-C, mg/dl

7.5 ± 26.1

5.0 ± 21.3

7.4 ± 23.7

6.4 ± 27.4

0.71

0.89

0.87

AS, IU

0.08 ± 15.3

−4.9 ± 7.3

−1.2 ± 8.5

−2.4 ± 8.4

0.10

0.74

0.31

ALT, IU

−12.6 ± 22.3

− 15.3 ± 19.9

−10.2 ± 17.4

−11.2 ± 12.2

0.58

0.34

0.80

GGT, IU

0.18 ± 28.9

−5.3 ± 13.5

−5.6 ± 15.6

7.6 ± 48.5

0.50

0.51

0.09

ALK, IU

−26.3 ± 74.7

−23.0 ± 38.1

2.2 ± 54.5

−33.3 ± 42.8

0.11

0.36

0.05

Vitamin D

−0.1 ± 6.4

2.1 ± 9.1

1.1 ± 6.4

0.73 ± 5.9

0.13

0.39

0.86

Hs-CRP,μg/ml

0.12 ± 3.2

0.0 ± 2.9

−0.38 ± 4.7

−1.3 ± 6.0

0.53

0.28

0.63

Leptin, ng/ml

−6.3 ± 17.9

−2.6 ± 12.6

−6.6 ± 21.1

−6.2 ± 13.3

0.53

0.55

0.61

Adiponectin, μg/m

−4.5 ± 12.2

−4.4 ± 14.2

0.05 ± 12.8

−1.8 ± 7.8

0.75

0.13

0.69

HSI

−2.2 ± 3.8

3.1 ± 4.5-

− 2.7 ± 4.9

−2.7 ± 4.1

0.56

0.92

0.54

APRI

0.0 ± 0.2

−0.04 ± 0.1

0.0 ± 0.1

−0.03 ± 0.1

0.20

0.95

0.73

  1. Values are expressed as the mean ± SD. BMI Body mass index, WC Waist circumference, HC Hip circumference, FBS Fasting blood glucose, Homa-IR Homeostatic Model Assessment for Insulin Resistance, HS index Hepatic steatosis index, APRI AST to Platelet Ratio Index, TC total cholesterol, TG Triglyceride, HDL-c High-density lipoproteins- cholesterol, LDL-c Low density lipoprotein- cholesterol, AST aspartate aminotransferase, ALT Alanine aminotransferase, GGT Gamma-glutamyl transferase, ALK Alkaline phosphatase, Hs-CRP High-sensitivity C-reactive protein
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us